ADAM28: Another ambivalent protease in cancer
Authors:
- 1 December 2020
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 494, 18-26
Abstract
No abstract availableKeywords
Funding Information
- WB health program of the Walloon Region (WB Health AEROGAL (1318023)
- Fonds National pour la Recherche Scientifique (FRS-FNRS Télévie (7462914F, 7652716F, 7650218F)
- Centre anticancéreux
- Foundation Against Cancer
- Foundation Léon Fredericq
This publication has 74 references indexed in Scilit:
- Identification of co‐expressed gene signatures in mouse B1, marginal zone and B2 B‐cell populationsImmunology, 2013
- Characterization of ADAM28 as a biomarker of bladder transitional cell carcinomas by urinary proteome analysisBiochemical and Biophysical Research Communications, 2011
- The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunityMolecular Immunology, 2011
- Deficiency of the Metalloproteinase-Disintegrin ADAM8 Is Associated with Thymic Hyper-CellularityPLOS ONE, 2010
- CD23/FcεRII: molecular multi-taskingClinical and Experimental Immunology, 2010
- Low density lipoprotein from patients with Type 2 diabetes increases expression of monocyte matrix metalloproteinase and ADAM metalloproteinase genesCardiovascular Diabetology, 2007
- High affinity interaction of integrin α4β1 (VLA‐4) and vascular cell adhesion molecule 1 (VCAM‐1) enhances migration of human melanoma cells across activated endothelial cell layersJournal of Cellular Physiology, 2007
- ADAMs in cancer cell proliferation and progressionCancer Science, 2007
- Molecular, biochemical, and cellular characterization of epididymal ADAMs, ADAM7 and ADAM28Biochemical and Biophysical Research Communications, 2005
- ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3Biochemical and Biophysical Research Communications, 2004